Law ❯ Securities Law ❯ Class Action

Securities Fraud

Shareholder Rights Investor Rights

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

The suits contend MoonLake overstated sonelokimab’s Nanobody advantages over BIMZELX after trial data coincided with a near-90% one-day share drop.

New aTyr Class Action Expands Investor Window After EFZO-FIT Failure